• Vaccine Name: L. donovani DNA Vaccine encoding KMP-11
• Target Pathogen: Leishmania donovani
• Target Disease: Visceral leishmaniasis
• Vaccine Ontology ID: VO_0011530
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: mouse
• Antigen: KNP-11(Bhaumik et al., 2009)
• KMP-11 gene engineering:
  • Type: DNA vaccine construction
  • Description: KMP-11was cloned into a pCMV-LIC vector for DNA vaccine candidate in mice (Bhaumik et al., 2009).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001147
  • Description: rmIL-12 (1 μg/injection) was used as an adjuvant and injected through s.c. route (Bhaumik et al., 2009).
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000230
• Immunization Route: Subcutaneous injection

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were either immunized with KMP-11 containing pCMV-LIC mammalian expression vector (pCMV-LIC KMP-11) or with blank-vector construct not harboring KMP-11 gene (pCMV-LIC). rmIL-12 (1 μg/injection) was used as an adjuvant and injected through s.c. route. 7 and 15 days before parasite challenge with LD or LM, 100 μg of endotoxin-free plasmid DNA construct (pCMV-LIC, and pCMV-LIC KMP-11) dissolved in saline and injected i.m. in the hind leg thigh muscle was used for immunization of BALB/c mice using 28-gauge needle (Bhaumik et al., 2009).
• Immune Response: KMP-11 DNA immunization alone effectively caused a significant increase in frequency of both IFN-γ producing CD4+ T and CD8+ T cells in mice challenged with either LM or LD (Bhaumik et al., 2009).
• Challenge Protocol: 6-weeks-old BALB/c mice were injected with 2 × 10^6 LD second-passage promastigotes suspended in saline through intracardiac route and 2 × 10^6 LM second-passage promastigotes through subcutaneous route in the hind footpad using a 28-gauge needle (Bhaumik et al., 2009).
• Efficacy: KMP-11 DNA vaccination alone in an experimental BALB/c mice model showed significant potential in terms of resolution of splenic and hepatic parasite burden against virulent LD challenge. KMP-11 DNA immunization significantly protects against L. donovani infection (Bhaumik et al., 2009).